Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT06180278
·
clinicaltrials.gov ↗
PHASE4
Phase
ACTIVE_NOT_RECRUITING
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
OTHER:
Blood tests
DRUG:
Inebilizumab
Sponsor
Amgen